CoChat
Sign Up
Cited by 150

The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.

Role of glutamate excitotoxicity and glutamate transporter EAAT2 in epilepsy: Opportunities for novel therapeutics development

Green, Jennifer Leigh, dos Santos, Wagner Ferreira, Fontana, Andréia Cristina Karklin·2021·Biochemical Pharmacology
DOI 10.1016/j.bcp.2021.114786PMC PMC8605998
Open this paper in CoChat — free account

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.bcp.2021.114786

Cites

5 of 5 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Excitotoxicity has been associated with several neurodegenerative disorders as well as epilepsy.

    “Excitotoxicity has been associated with several neurodegenerative disorders as well as epilepsy [124,125].”

    From Global identification of neuronal and astrocytic integral membrane proteins that require Retromer for their endosomal recycling (2026) · cites this paper as [125]

    The 'Glutamate Excitotoxicity and Epilepsy' section links excitotoxicity to seizures and discusses motor-neuron degeneration in an ALS-related model. It does not substantiate the broader claim that excitotoxicity is associated with several neurodegenerative disorders; the discussion identifies ALS but not several such disorders. (LLM, conf=0.82)

    Experimental — accuracy not yet measured

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Flagged first, then by citations

Research works printed but not linked: 198

  1. Ali, 2016, Epilepsy: A Disruptive Force in History, World Neurosurg., 90, 685, 10.1016/j.wneu.2015.11.060 · DOI
  2. K.K. Takahashi, Glutamate transporter EAAT2: regulation, function, and potential as a therapeutic target for neurological and psychiatric disease, Cellular and molecular life sciences : CMLS 72 3489-3506. 10.1007/s00018-015-1937-8. · DOI
  3. Patel, 2019, Neuron-glia interactions in the pathophysiology of epilepsy, Nat. Rev. Neurosci., 20, 282, 10.1038/s41583-019-0126-4 · DOI
  4. Chapman, 2000, Glutamate and epilepsy, The Journal of nutrition, 130, 1043s, 10.1093/jn/130.4.1043S · DOI
  5. Werner, 2015, Review: Classical neurotransmitters and neuropeptides involved in generalized epilepsy in a multi-neurotransmitter system: How to improve the antiepileptic effect?, Epilepsy & behavior : E&B
  6. Walker, 2018, Pathophysiology of status epilepticus, Neurosci. Lett., 667, 84, 10.1016/j.neulet.2016.12.044 · DOI
  7. Albrecht, 2017, Mechanisms of Excessive Extracellular Glutamate Accumulation in Temporal Lobe Epilepsy, Neurochem. Res., 42, 1724, 10.1007/s11064-016-2105-8 · DOI
  8. Riviello, 2003, Classification of seizures and epilepsy, Current Neurol. Neurosci. Rep., 3, 325, 10.1007/s11910-003-0010-4 · DOI
  9. S. Wiebe, Epidemiology of temporal lobe epilepsy, The Canadian journal of neurological sciences. Le journal canadien des sciences neurologiques 27 Suppl 1 (2000) S6-10; discussion S20-11. 10.1017/s0317167100000561. · DOI
  10. Aronica, 2017, Neuropathology of epilepsy, Handbook Clinic. Neurol., 145, 193
  11. Engelborghs, 2000, Pathophysiology of epilepsy, Acta Neurol. Belg., 100, 201
  12. Knake, 2009, Status epilepticus: a critical review, Epilepsy Behav. E&B, 15, 10, 10.1016/j.yebeh.2009.02.027 · DOI
  13. Lothman, 1990, The biochemical basis and pathophysiology of status epilepticus, Neurology, 40, 13
  14. Delgado-Escueta, 1983, Status epilepticus: summary, Adv. Neurol., 34, 537
  15. Dong, 2009, Molecular mechanisms of excitotoxicity and their relevance to pathogenesis of neurodegenerative diseases, Acta Pharmacol. Sin., 30, 379, 10.1038/aps.2009.24 · DOI · Paper page
  16. J.O. McNamara, Y.Z. Huang, A.S. Leonard, Molecular signaling mechanisms underlying epileptogenesis, Science's STKE : signal transduction knowledge environment 2006 (2006) re12. 10.1126/stke.3562006re12. · DOI
  17. Pitkanen, 2011, Mechanisms of epileptogenesis and potential treatment targets, Lancet Neurol., 10, 173, 10.1016/S1474-4422(10)70310-0 · DOI
  18. Lin, 2012, Glutamate transporter EAAT2: a new target for the treatment of neurodegenerative diseases, Future Med. Chem., 4, 1689, 10.4155/fmc.12.122 · DOI
  19. Jarero-Basulto, 2018, Interactions Between Epilepsy and Plasticity, Pharmaceuticals (Basel), 11, 17, 10.3390/ph11010017 · DOI
  20. Vasilev, 2018, Transient Morphological Alterations in the Hippocampus After Pentylenetetrazole-Induced Seizures in Rats, Neurochem. Res., 43, 1671, 10.1007/s11064-018-2583-y · DOI
  21. Dhaher, 2021, Network-Related Changes in Neurotransmitters and Seizure Propagation During Rodent Epileptogenesis, Neurology, 10.1212/WNL.0000000000011846 · DOI
  22. Barker-Haliski, 2015, Glutamatergic Mechanisms Associated with Seizures and Epilepsy, Cold Spring Harbor Perspect. Med., 5, 10.1101/cshperspect.a022863 · DOI
  23. Rakhade, 2009, Epileptogenesis in the immature brain: emerging mechanisms, Nat. Rev. Neurol., 5, 380, 10.1038/nrneurol.2009.80 · DOI
  24. Bialer, 2010, Key factors in the discovery and development of new antiepileptic drugs, Nat. Rev. Drug Discovery, 9, 68, 10.1038/nrd2997 · DOI
  25. Löscher, 2020, Drug Resistance in Epilepsy: Clinical Impact, Potential Mechanisms, and New Innovative Treatment Options, Pharmacol. Rev., 72, 606, 10.1124/pr.120.019539 · DOI
  26. Chen, 2018, Treatment Outcomes in Patients With Newly Diagnosed Epilepsy Treated With Established and New Antiepileptic Drugs: A 30-Year Longitudinal Cohort Study, JAMA Neurol., 75, 279, 10.1001/jamaneurol.2017.3949 · DOI
  27. Sankar, 2004, Mechanisms of action for the commonly used antiepileptic drugs: relevance to antiepileptic drug-associated neurobehavioral adverse effects, J. Child Neurol., 19, S6
  28. de Kinderen, 2014, Side-effects of antiepileptic drugs: The economic burden, Seizure J. British Epilepsy Assoc., 23, 184, 10.1016/j.seizure.2013.11.009 · DOI
  29. Cramer, 2010, Adverse effects of antiepileptic drugs: a brief overview of important issues, Expert Rev. Neurother., 10, 885, 10.1586/ern.10.71 · DOI
  30. Zwart, 2014, Perampanel, an antagonist of alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptors, for the treatment of epilepsy: studies in human epileptic brain and nonepileptic brain and in rodent models, J. Pharmacol. Exp. Therapeut., 351, 124, 10.1124/jpet.114.212779 · DOI
  31. Klein, 2020, No prevention or cure of epilepsy as yet, Neuropharmacology, 168, 10.1016/j.neuropharm.2019.107762 · DOI
  32. Peterson, 2019, Regulation of Synaptosomal GLT-1 and GLAST during Epileptogenesis, Neuroscience, 411, 185, 10.1016/j.neuroscience.2019.05.048 · DOI
  33. Fontana, 2015, Current approaches to enhance glutamate transporter function and expression, J. Neurochem., 134, 982, 10.1111/jnc.13200 · DOI
  34. Sheldon, 2007, The role of glutamate transporters in neurodegenerative diseases and potential opportunities for intervention, Neurochem. Int., 51, 333, 10.1016/j.neuint.2007.03.012 · DOI
  35. Willard, 2013, Glutamate, glutamate receptors, and downstream signaling pathways, Int J Biol Sci, 9, 948, 10.7150/ijbs.6426 · DOI
  36. Danbolt, 2001, Glutamate uptake, Prog. Neurobiol., 65, 1, 10.1016/S0301-0082(00)00067-8 · DOI · Paper page
  37. Vandenberg, 2013, Mechanisms of glutamate transport, Physiol. Rev., 93, 1621, 10.1152/physrev.00007.2013 · DOI
  38. van den Berg, 1971, A simulation study of brain compartments Metabolism of glutamate and related substances in mouse brain, Biochem. J., 123, 211, 10.1042/bj1230211 · DOI
  39. Westergaard, 1995, Metabolic trafficking between neurons and astrocytes: the glutamate/glutamine cycle revisited, Dev. Neurosci., 17, 203, 10.1159/000111288 · DOI
  40. Shigeri, 2004, Molecular pharmacology of glutamate transporters, EAATs and VGLUTs, Brain Res. Brain Res. Rev., 45, 250, 10.1016/j.brainresrev.2004.04.004 · DOI
  41. Pines, 1992, Cloning and expression of a rat brain L-glutamate transporter, Nature, 360, 464, 10.1038/360464a0 · DOI
  42. Haugeto, 1996, Brain glutamate transporter proteins form homomultimers, J. Biol. Chem., 271, 27715, 10.1074/jbc.271.44.27715 · DOI
  43. Tanaka, 1997, Epilepsy and exacerbation of brain injury in mice lacking the glutamate transporter GLT-1, Science, 276, 1699, 10.1126/science.276.5319.1699 · DOI
  44. Lehre, 1998, The number of glutamate transporter subtype molecules at glutamatergic synapses: chemical and stereological quantification in young adult rat brain, J. Neurosci. Off. J. Soc. Neurosci., 18, 8751, 10.1523/JNEUROSCI.18-21-08751.1998 · DOI
  45. Suchak, 2003, The 'glial' glutamate transporter, EAAT2 (Glt-1) accounts for high affinity glutamate uptake into adult rodent nerve endings, J. Neurochem., 84, 522, 10.1046/j.1471-4159.2003.01553.x · DOI
  46. Scofield, 2014, Astrocytic dysfunction and addiction: consequences of impaired glutamate homeostasis, Neurosci. Rev. J. Bring. Neurobiol. Neurol. Psychiat., 20, 610
  47. Maragakis, 2004, Altered expression of the glutamate transporter EAAT2b in neurological disease, Ann. Neurol., 55, 469, 10.1002/ana.20003 · DOI
  48. Lauriat, 2007, EAAT2 regulation and splicing: relevance to psychiatric and neurological disorders, Mol. Psychiatry, 12, 1065, 10.1038/sj.mp.4002065 · DOI
  49. Kim, 2011, Role of excitatory amino acid transporter-2 (EAAT2) and glutamate in neurodegeneration: opportunities for developing novel therapeutics, J. Cell. Physiol., 226, 2484, 10.1002/jcp.22609 · DOI
  50. Nilsson, 1990, Changes in cortical extracellular levels of energy-related metabolites and amino acids following concussive brain injury in rats, J. Cerebral Blood Flow Metab. Off. J. Int. Soc. Cereb. Blood Flow Metab., 10, 631, 10.1038/jcbfm.1990.115 · DOI
  51. Vespa, 1998, Increase in extracellular glutamate caused by reduced cerebral perfusion pressure and seizures after human traumatic brain injury: a microdialysis study, J. Neurosurg., 89, 971, 10.3171/jns.1998.89.6.0971 · DOI
  52. Faden, 1989, The role of excitatory amino acids and NMDA receptors in traumatic brain injury, Science, 244, 798, 10.1126/science.2567056 · DOI · Paper page
  53. Raghupathi, 2004, Cell death mechanisms following traumatic brain injury, Brain Pathol, 14, 215, 10.1111/j.1750-3639.2004.tb00056.x · DOI
  54. Lewerenz, 2006, Cooperative action of glutamate transporters and cystine/glutamate antiporter system Xc- protects from oxidative glutamate toxicity, J. Neurochem., 98, 916, 10.1111/j.1471-4159.2006.03921.x · DOI
  55. H. Sato, M. Tamba, S. Okuno, K. Sato, K. Keino-Masu, M. Masu, S. Bannai, Distribution of cystine/glutamate exchange transporter, system x(c)-, in the mouse brain, The Journal of neuroscience : the official journal of the Society for Neuroscience 22 (2002) 8028-8033. · DOI
  56. Sorensen, 2018, High expression of cystine-glutamate antiporter xCT (SLC7A11) is an independent biomarker for epileptic seizures at diagnosis in glioma, J. Neurooncol., 138, 49, 10.1007/s11060-018-2785-9 · DOI
  57. Zorec, 2012, Astroglial excitability and gliotransmission: an appraisal of Ca2+ as a signalling route, ASN neuro, 4, 10.1042/AN20110061 · DOI
  58. Perea, 2009, Tripartite synapses: astrocytes process and control synaptic information, Trends Neurosci., 32, 421, 10.1016/j.tins.2009.05.001 · DOI · Paper page
  59. Peterson, 2020, Astrocyte Glutamate Uptake and Signaling as Novel Targets for Antiepileptogenic Therapy, Front. Neurol., 11, 10.3389/fneur.2020.01006 · DOI
  60. Wetherington, 2008, Astrocytes in the Epileptic Brain, Neuron, 58, 168, 10.1016/j.neuron.2008.04.002 · DOI
  61. Hubbard, 2016, Regulation of astrocyte glutamate transporter-1 (GLT1) and aquaporin-4 (AQP4) expression in a model of epilepsy, Exp. Neurol., 283, 85, 10.1016/j.expneurol.2016.05.003 · DOI
  62. S. Sarac, S. Afzal, H. Broholm, F.F. Madsen, T. Ploug, H. Laursen, Excitatory amino acid transporters EAAT-1 and EAAT-2 in temporal lobe and hippocampus in intractable temporal lobe epilepsy, APMIS : acta pathologica, microbiologica, et immunologica Scandinavica 117 (2009) 291-301. 10.1111/j.1600-0463.2009.02443.x. · DOI
  63. Tilleux, 2007, Neuroinflammation and regulation of glial glutamate uptake in neurological disorders, J. Neurosci. Res., 85, 2059, 10.1002/jnr.21325 · DOI · Paper page
  64. Aguado, 2002, Neuronal activity regulates correlated network properties of spontaneous calcium transients in astrocytes in situ, The Journal of neuroscience : the official journal of the Society for, Neuroscience, 22, 9430, 10.1523/JNEUROSCI.22-21-09430.2002 · DOI
  65. Haroon, 2017, Inflammation, Glutamate, and Glia: A Trio of Trouble in Mood Disorders, Neuropsychopharmacology : official publication of the American College of, Neuropsychopharmacology, 42, 193, 10.1038/npp.2016.199 · DOI · Paper page
  66. Vargas-Sanchez, 2018, Astroglial role in the pathophysiology of status epilepticus: an overview, Oncotarget 9, 26954–26976
  67. Vezzani, 2007, New roles for interleukin-1 Beta in the mechanisms of epilepsy, Epilepsy Curr. Am. Epilepsy Soc., 7, 45, 10.1111/j.1535-7511.2007.00165.x · DOI
  68. Crino, 2019, Mechanistic target of rapamycin (mTOR) signaling in status epilepticus, Epilepsy Behav. E&B, 101
  69. Jeong, 2021, Vascular endothelial growth factor receptor-3 regulates astroglial glutamate transporter-1 expression via mTOR activation in reactive astrocytes following pilocarpine-induced status epilepticus, Glia, 69, 296, 10.1002/glia.23897 · DOI
  70. Robinson, 2020, Astroglial glutamate transporters coordinate excitatory signaling and brain energetics, Neurochem. Int.
  71. Boison, 2018, Epilepsy and astrocyte energy metabolism, Glia, 66, 1235, 10.1002/glia.23247 · DOI
  72. Robinson, 2020, Glutamate Transporters and Mitochondria: Signaling, Co-compartmentalization, Functional Coupling, and Future Directions, Neurochem. Res., 45, 526, 10.1007/s11064-020-02974-8 · DOI
  73. Rogawski, 2016, Mechanisms of Action of Antiseizure Drugs and the Ketogenic Diet, Cold Spring Harbor Persp. Med., 6
  74. Eid, 2004, Loss of glutamine synthetase in the human epileptogenic hippocampus: possible mechanism for raised extracellular glutamate in mesial temporal lobe epilepsy, Lancet, 363, 28, 10.1016/S0140-6736(03)15166-5 · DOI
  75. Eid, 2019, Astrocytes and Glutamine Synthetase in Epileptogenesis, J. Neurosci. Res., 97, 1345, 10.1002/jnr.24267 · DOI · Paper page
  76. Zhou, 2019, Selective deletion of glutamine synthetase in the mouse cerebral cortex induces glial dysfunction and vascular impairment that precede epilepsy and neurodegeneration, Neurochem. Int., 123, 22, 10.1016/j.neuint.2018.07.009 · DOI
  77. O. Devinsky, A. Vezzani, S. Najjar, N.C. De Lanerolle, M.A. Rogawski, Glia and epilepsy: excitability and inflammation, Trends in neurosciences 36 174-184. 10.1016/j.tins.2012.11.008. · DOI
  78. Bedner, 2016, Neuron-glia interaction in epilepsy, J. Neurosci. Res., 94, 779, 10.1002/jnr.23800 · DOI
  79. Olney, 1986, Excitotoxic mechanisms of epileptic brain damage, Adv. Neurol., 44, 857
  80. Smolders, 1997, NMDA receptor-mediated pilocarpine-induced seizures: characterization in freely moving rats by microdialysis, Br. J. Pharmacol., 121, 1171, 10.1038/sj.bjp.0701231 · DOI
  81. During, 1993, Extracellular hippocampal glutamate and spontaneous seizure in the conscious human brain, Lancet, 341, 1607, 10.1016/0140-6736(93)90754-5 · DOI
  82. Cavus, 2005, Extracellular metabolites in the cortex and hippocampus of epileptic patients, Ann. Neurol., 57, 226, 10.1002/ana.20380 · DOI
  83. McDonough, 1997, Neuropharmacological mechanisms of nerve agent-induced seizure and neuropathology, Neurosci. Biobehav. Rev., 21, 559, 10.1016/S0149-7634(96)00050-4 · DOI
  84. Thomas, 2004, Hippocampal microdialysis during spontaneous intraoperative epileptiform activity, Acta Neurochir., 146, 143, 10.1007/s00701-003-0189-9 · DOI
  85. Coulter, 2012, Astrocytic regulation of glutamate homeostasis in epilepsy, Glia, 60, 1215, 10.1002/glia.22341 · DOI
  86. Jabs, 2008, Astrocytic function and its alteration in the epileptic brain, Epilepsia, 49, 3, 10.1111/j.1528-1167.2008.01488.x · DOI
  87. Matute, 2006, Glutamate-mediated glial injury: mechanisms and clinical importance, Glia, 53, 212, 10.1002/glia.20275 · DOI
  88. Ding, 2007, Enhanced astrocytic Ca2+ signals contribute to neuronal excitotoxicity after status epilepticus, The Journal of neuroscience : the official journal of the Society for, Neuroscience, 27, 10674, 10.1523/JNEUROSCI.2001-07.2007 · DOI
  89. Rothstein, 1993, Chronic inhibition of glutamate uptake produces a model of slow neurotoxicity, PNAS, 90, 6591, 10.1073/pnas.90.14.6591 · DOI
  90. Rothstein, 1995, Neuroprotective strategies in a model of chronic glutamate-mediated motor neuron toxicity, J. Neurochem., 65, 643, 10.1046/j.1471-4159.1995.65020643.x · DOI
  91. Bar-Peled, 1999, Cultured motor neurons possess calcium-permeable AMPA/kainate receptors, NeuroReport, 10, 855, 10.1097/00001756-199903170-00034 · DOI
  92. Maragakis, 2003, Topiramate protects against motor neuron degeneration in organotypic spinal cord cultures but not in G93A SOD1 transgenic mice, Neurosci. Lett., 338, 107, 10.1016/S0304-3940(02)01386-1 · DOI
  93. Rogawski, 2013, AMPA receptors as a molecular target in epilepsy therapy, Acta Neurol. Scand Suppl., 9, 10.1111/ane.12099 · DOI
  94. Tian, 2005, An astrocytic basis of epilepsy, Nat. Med., 11, 973, 10.1038/nm1277 · DOI · Paper page
  95. Benarroch, 2009, Astrocyte-neuron interactions: implications for epilepsy, Neurology, 73, 1323, 10.1212/WNL.0b013e3181bd432d · DOI
  96. Wasterlain, 2013, Trafficking of NMDA receptors during status epilepticus: therapeutic implications, Epilepsia, 54, 78, 10.1111/epi.12285 · DOI
  97. Cunha, 2007, Glutamate binding is altered in hippocampus and cortex of Wistar rats after pilocarpine-induced Status Epilepticus, Neurosci. Lett., 424, 51, 10.1016/j.neulet.2007.07.010 · DOI
  98. Lopes, 2013, Time-dependent modulation of AMPA receptor phosphorylation and mRNA expression of NMDA receptors and glial glutamate transporters in the rat hippocampus and cerebral cortex in a pilocarpine model of epilepsy, Exp. Brain Res., 226, 153, 10.1007/s00221-013-3421-8 · DOI · Paper page
  99. Frasca, 2011, Misplaced NMDA receptors in epileptogenesis contribute to excitotoxicity, Neurobiol. Dis., 43, 507, 10.1016/j.nbd.2011.04.024 · DOI
  100. A. Das, G.C.t. Wallace, C. Holmes, M.L. McDowell, J.A. Smith, J.D. Marshall, L. Bonilha, J.C. Edwards, S.S. Glazier, S.K. Ray, N.L. Banik, Hippocampal tissue of patients with refractory temporal lobe epilepsy is associated with astrocyte activation, inflammation, and altered expression of channels and receptors, Neuroscience 220 (2012) 237-246. 10.1016/j.neuroscience.2012.06.002. · DOI
  101. McGinnity, 2015, NMDA receptor binding in focal epilepsies, J. Neurol. Neurosurg. Psychiatry, 86, 1150, 10.1136/jnnp-2014-309897 · DOI
  102. Haj-Yasein, 2011, Evidence that compromised K+ spatial buffering contributes to the epileptogenic effect of mutations in the human Kir4.1 gene (KCNJ10), Glia, 59, 1635, 10.1002/glia.21205 · DOI
  103. Okamoto, 2010, Whole transcriptome analysis of the hippocampus: toward a molecular portrait of epileptogenesis, BMC Genomics, 11, 230, 10.1186/1471-2164-11-230 · DOI
  104. Naylor, 2013, Rapid surface accumulation of NMDA receptors increases glutamatergic excitation during status epilepticus, Neurobiol. Dis., 54, 225, 10.1016/j.nbd.2012.12.015 · DOI
  105. Ryley Parrish, 2013, Status epilepticus triggers early and late alterations in brain-derived neurotrophic factor and NMDA glutamate receptor Grin2b DNA methylation levels in the hippocampus, Neuroscience, 248, 602, 10.1016/j.neuroscience.2013.06.029 · DOI
  106. DeLorenzo, 1998, Prolonged activation of the N-methyl-D-aspartate receptor-Ca2+ transduction pathway causes spontaneous recurrent epileptiform discharges in hippocampal neurons in culture, PNAS, 95, 14482, 10.1073/pnas.95.24.14482 · DOI
  107. Sutula, 1996, NMDA Receptor Dependence of Kindling and Mossy Fiber Sprouting: Evidence that the NMDA Receptor Regulates Patterning of Hippocampal Circuits in the Adult Brain, The J. Neurosci., 16, 7398, 10.1523/JNEUROSCI.16-22-07398.1996 · DOI
  108. McNamara, 1995, NMDA receptor blockade prevents kainate induction of protein F1/GAP-43 mRNA in hippocampal granule cells and subsequent mossy fiber sprouting in the rat, Brain Res. Mol. Brain Res., 33, 22, 10.1016/0169-328X(95)00083-5 · DOI
  109. F. Dorandeu, L. Barbier, F. Dhote, G. Testylier, P. Carpentier, Ketamine combinations for the field treatment of soman-induced self-sustaining status epilepticus. Review of current data and perspectives, Chemico-biological interactions 203 (2013) 154-159. 10.1016/j.cbi.2012.09.013. · DOI
  110. Dorandeu, 2013, Treatment of status epilepticus with ketamine, are we there yet?, CNS Neurosci Ther, 19, 411, 10.1111/cns.12096 · DOI
  111. Jimenez-Mateos, 2012, Silencing microRNA-134 produces neuroprotective and prolonged seizure-suppressive effects, Nat. Med., 18, 1087, 10.1038/nm.2834 · DOI
  112. Wada, 1992, The NMDA receptor antagonist MK-801 has a dissociative effect on seizure activity of hippocampal-kindled cats, Pharmacol. Biochem. Behav., 43, 1269, 10.1016/0091-3057(92)90513-F · DOI
  113. S.A. Lipton, Failures and successes of NMDA receptor antagonists: molecular basis for the use of open-channel blockers like memantine in the treatment of acute and chronic neurologic insults, NeuroRx : the journal of the American Society for Experimental NeuroTherapeutics 1 (2004) 101-110. 10.1602/neurorx.1.1.101. · DOI
  114. Lim, 2003, Ketamine associated psychedelic effects and dependence, Singapore Med. J., 44, 31
  115. Hanada, 2020, Ionotropic Glutamate Receptors in Epilepsy: A Review Focusing on AMPA and NMDA Receptors, Biomolecules, 10, 10.3390/biom10030464 · DOI
  116. Zaitsev, 2020, Neurobiology, Functions, and Relevance of Excitatory Amino Acid Transporters (EAATs) to Treatment of Refractory Epilepsy, CNS Drugs, 34, 1089, 10.1007/s40263-020-00764-y · DOI
  117. Rothstein, 1996, Knockout of glutamate transporters reveals a major role for astroglial transport in excitotoxicity and clearance of glutamate, Neuron, 16, 675, 10.1016/S0896-6273(00)80086-0 · DOI · Paper page
  118. Sugimoto, 2018, Region-specific deletions of the glutamate transporter GLT1 differentially affect seizure activity and neurodegeneration in mice, Glia, 66, 777, 10.1002/glia.23281 · DOI
  119. Loewen, 2019, Genetic and pharmacological manipulation of glial glutamate transporters does not alter infection-induced seizure activity, Exp. Neurol., 318, 50, 10.1016/j.expneurol.2019.04.010 · DOI
  120. Akbar, 1997, Expression of glial glutamate transporters GLT-1 and GLAST is unchanged in the hippocampus in fully kindled rats, Neuroscience, 78, 351, 10.1016/S0306-4522(96)00570-2 · DOI
  121. Tessler, 1999, Expression of the glutamate transporters in human temporal lobe epilepsy, Neuroscience, 88, 1083, 10.1016/S0306-4522(98)00301-7 · DOI
  122. Simantov, 1999, Changes in expression of neuronal and glial glutamate transporters in rat hippocampus following kainate-induced seizure activity, Brain Res. Mol. Brain Res., 65, 112, 10.1016/S0169-328X(98)00349-0 · DOI
  123. Doi, 2009, Role of glutamate and GABA transporters in development of pentylenetetrazol-kindling, Neurochem. Res., 34, 1324, 10.1007/s11064-009-9912-0 · DOI
  124. Munoz-Ballester, 2019, In vivo glutamate clearance defects in a mouse model of Lafora disease, Exp. Neurol., 320, 10.1016/j.expneurol.2019.112959 · DOI
  125. Mathern, 1999, Hippocampal GABA and glutamate transporter immunoreactivity in patients with temporal lobe epilepsy, Neurology, 52, 453, 10.1212/WNL.52.3.453 · DOI
  126. Proper, 2002, Distribution of glutamate transporters in the hippocampus of patients with pharmaco-resistant temporal lobe epilepsy, Brain J. Neurol., 125, 32, 10.1093/brain/awf001 · DOI
  127. Hoogland, 2004, Alternative splicing of glutamate transporter EAAT2 RNA in neocortex and hippocampus of temporal lobe epilepsy patients, Epilepsy Res., 59, 75, 10.1016/j.eplepsyres.2004.03.003 · DOI
  128. Bjornsen, 2007, Changes in glial glutamate transporters in human epileptogenic hippocampus: inadequate explanation for high extracellular glutamate during seizures, Neurobiol. Dis., 25, 319, 10.1016/j.nbd.2006.09.014 · DOI
  129. Rakhade, 2008, Focal reduction of neuronal glutamate transporters in human neocortical epilepsy, Epilepsia, 49, 226, 10.1111/j.1528-1167.2007.01310.x · DOI
  130. Jen, 2005, Mutation in the glutamate transporter EAAT1 causes episodic ataxia, hemiplegia, and seizures, Neurology, 65, 529, 10.1212/01.WNL.0000172638.58172.5a · DOI
  131. de Vries, 2009, Episodic ataxia associated with EAAT1 mutation C186S affecting glutamate reuptake, Arch. Neurol., 66, 97, 10.1001/archneurol.2008.535 · DOI
  132. Winter, 2012, A point mutation associated with episodic ataxia 6 increases glutamate transporter anion currents, Brain J. Neurol., 135, 3416, 10.1093/brain/aws255 · DOI
  133. P. Kovermann, V. Untiet, Y. Kolobkova, M. Engels, S. Baader, K. Schilling, C. Fahlke, Increased glutamate transporter-associated anion currents cause glial apoptosis in episodic ataxia 6, Brain Commun 2 (2020) fcaa022. 10.1093/braincomms/fcaa022. · DOI
  134. Parinejad, 2016, Disruption of an EAAT-Mediated Chloride Channel in a Drosophila Model of Ataxia, The Journal of neuroscience : the official journal of the Society for, Neuroscience, 36, 7640, 10.1523/JNEUROSCI.0197-16.2016 · DOI
  135. Chivukula, 2020, Functional consequences of SLC1A3 mutations associated with episodic ataxia 6, Hum. Mutat., 41, 1892, 10.1002/humu.24089 · DOI
  136. De Novo Mutations in SLC1A2 and CACNA1A Are Important Causes of Epileptic Encephalopathies, American journal of human genetics 99 (2016) 287-298. 10.1016/j.ajhg.2016.06.003. · DOI · Paper page
  137. Guella, 2017, De Novo Mutations in YWHAG Cause Early-Onset Epilepsy, Am. J. Human Genet., 101, 300, 10.1016/j.ajhg.2017.07.004 · DOI
  138. Stergachis, 2019, Recurrent SLC1A2 variants cause epilepsy via a dominant negative mechanism, Ann. Neurol., 85, 921, 10.1002/ana.25477 · DOI
  139. Canul-Tec, 2017, Structure and allosteric inhibition of excitatory amino acid transporter 1, Nature, 544, 446, 10.1038/nature22064 · DOI
  140. Ueda, 2007, Functional role for redox in the epileptogenesis: molecular regulation of glutamate in the hippocampus of FeCl3-induced limbic epilepsy model, Exp. Brain Res., 181, 571, 10.1007/s00221-007-0954-8 · DOI
  141. Miller, 1997, Alterations in glutamate transporter protein levels in kindling-induced epilepsy, J. Neurochem., 68, 1564, 10.1046/j.1471-4159.1997.68041564.x · DOI
  142. M. Sakurai, H. Kurokawa, A. Shimada, K. Nakamura, H. Miyata, T. Morita, Excitatory amino acid transporter 2 downregulation correlates with thalamic neuronal death following kainic acid-induced status epilepticus in rat, Neuropathology : official journal of the Japanese Society of Neuropathology 35 (2015) 1-9. 10.1111/neup.12141. · DOI
  143. Zhang, 2019, SLC1A2 mediates refractory temporal lobe epilepsy with an initial precipitating injury by targeting the glutamatergic synapse pathway, IUBMB Life, 71, 213, 10.1002/iub.1956 · DOI
  144. Wong, 2003, Impaired glial glutamate transport in a mouse tuberous sclerosis epilepsy model, Ann. Neurol., 54, 251, 10.1002/ana.10648 · DOI
  145. Zeng, 2007, Abnormal glutamate homeostasis and impaired synaptic plasticity and learning in a mouse model of tuberous sclerosis complex, Neurobiol. Dis., 28, 184, 10.1016/j.nbd.2007.07.015 · DOI
  146. Goodrich, 2013, Ceftriaxone treatment after traumatic brain injury restores expression of the glutamate transporter, GLT-1, reduces regional gliosis, and reduces post-traumatic seizures in the rat, J. Neurotrauma, 30, 1434, 10.1089/neu.2012.2712 · DOI
  147. Guo, 2010, Abnormal expressions of glutamate transporters and metabotropic glutamate receptor 1 in the spontaneously epileptic rat hippocampus, Brain Res. Bull., 81, 510, 10.1016/j.brainresbull.2009.10.008 · DOI
  148. Umpierre, 2019, Conditional Knock-out of mGluR5 from Astrocytes during Epilepsy Development Impairs High-Frequency Glutamate Uptake, J. Neurosci., 39, 727, 10.1523/JNEUROSCI.1148-18.2018 · DOI
  149. Y. David, L.P. Cacheaux, S. Ivens, E. Lapilover, U. Heinemann, D. Kaufer, A. Friedman, Astrocytic dysfunction in epileptogenesis: consequence of altered potassium and glutamate homeostasis?, The Journal of neuroscience : the official journal of the Society for Neuroscience 29 (2009) 10588-10599. 10.1523/jneurosci.2323-09.2009. · DOI
  150. Liu, 2019, Endothelial Cdk5 deficit leads to the development of spontaneous epilepsy through CXCL1/CXCR2-mediated reactive astrogliosis, J. Exp. Med.
  151. Hong, 2021, Sex-related Differences in Glial Fibrillary Acidic Protein-positive GABA Regulate Neuropathology Following Pilocarpine-induced Status Epilepticus, Neuroscience, 472, 157, 10.1016/j.neuroscience.2021.08.002 · DOI
  152. Kong, 2012, Increased glial glutamate transporter EAAT2 expression reduces epileptogenic processes following pilocarpine-induced status epilepticus, Neurobiol. Dis., 47, 145, 10.1016/j.nbd.2012.03.032 · DOI
  153. Kong, 2014, Small-molecule activator of glutamate transporter EAAT2 translation provides neuroprotection, J. Clinic. Invest., 124, 1255, 10.1172/JCI66163 · DOI · Paper page
  154. Lee, 2008, Mechanism of ceftriaxone induction of excitatory amino acid transporter-2 expression and glutamate uptake in primary human astrocytes, J. Biol. Chem., 283, 13116, 10.1074/jbc.M707697200 · DOI
  155. Zeng, 2010, Modulation of astrocyte glutamate transporters decreases seizures in a mouse model of Tuberous Sclerosis Complex, Neurobiol. Dis., 37, 764, 10.1016/j.nbd.2009.12.020 · DOI
  156. A.V. Jelenkovic, M.D. Jovanovic, D.D. Stanimirovic, D.D. Bokonjic, G.G. Ocic, B.S. Boskovic, Beneficial effects of ceftriaxone against pentylenetetrazole-evoked convulsions, Experimental biology and medicine (Maywood, N.J.) 233 (2008) 1389-1394. 10.3181/0803-rm-83. · DOI
  157. Takahashi, 2015, Glutamate transporter EAAT2: regulation, function, and potential as a therapeutic target for neurological and psychiatric disease, Cell Mol Life Sci, 72, 3489, 10.1007/s00018-015-1937-8 · DOI
  158. H.A. Fachim, R. Guizzo, A.O.S. Cunha, A.C. Pereira, L.C. Dos Anjos, M.R. Mortari, W.F. Dos Santos, Ceftriaxone pretreatment confers neuroprotection in rats with acute glaucoma and reduces the score of seizures induced by pentylenotetrazole in mice, Journal of biochemical and molecular toxicology (2020) e22578. 10.1002/jbt.22578. · DOI
  159. Li, 2021, Treatment effects of the combination of ceftriaxone and valproic acid on neuronal and behavioral functions in an epilepsy rat model, Exp. Physiol. n/a, 10.1113/EP089624 · DOI
  160. Ramandi, 2021, Pharmacological upregulation of GLT-1 alleviates the cognitive impairments in the animal model of temporal lobe epilepsy, PLoS ONE, 16, 10.1371/journal.pone.0246068 · DOI
  161. Traynor, 2006, Neuroprotective agents for clinical trials in ALS: a systematic assessment, Neurology, 67, 20, 10.1212/01.wnl.0000223353.34006.54 · DOI
  162. Wang, 2004, Mechanisms underlying the riluzole inhibition of glutamate release from rat cerebral cortex nerve terminals (synaptosomes), Neuroscience, 125, 191, 10.1016/j.neuroscience.2004.01.019 · DOI
  163. Kretschmer, 1998, Riluzole, a glutamate release inhibitor, and motor behavior, Naunyn-Schmiedeberg's Arch. Pharmacol., 358, 181, 10.1007/PL00005241 · DOI
  164. Azbill, 2000, Riluzole increases high-affinity glutamate uptake in rat spinal cord synaptosomes, Brain Res., 871, 175, 10.1016/S0006-8993(00)02430-6 · DOI
  165. Carbone, 2012, Riluzole elevates GLT-1 activity and levels in striatal astrocytes, Neurochem. Int., 60, 31, 10.1016/j.neuint.2011.10.017 · DOI
  166. Fumagalli, 2008, Riluzole enhances the activity of glutamate transporters GLAST, GLT1 and EAAC1, Eur. J. Pharmacol., 578, 171, 10.1016/j.ejphar.2007.10.023 · DOI
  167. Frizzo, 2004, Riluzole enhances glutamate uptake in rat astrocyte cultures, Cell. Mol. Neurobiol., 24, 123, 10.1023/B:CEMN.0000012717.37839.07 · DOI
  168. Farinato, 2018, Effects of Benzothiazolamines on Voltage-Gated Sodium Channels, Handb. Exp. Pharmacol., 246, 233, 10.1007/164_2017_46 · DOI
  169. Yoshida, 2001, Effect of riluzole on the acquisition and expression of amygdala kindling, Epilepsy Res., 46, 101, 10.1016/S0920-1211(01)00251-0 · DOI
  170. Borowicz, 2004, Riluzole enhances the anti-seizure action of conventional antiepileptic drugs against pentetrazole-induced convulsions in mice, Pol. J. Pharmacol., 56, 187
  171. Peña, 2000, Seizures and neurodegeneration induced by 4-aminopyridine in rat hippocampus in vivo: role of glutamate- and GABA-mediated neurotransmission and of ion channels, Neuroscience, 101, 547, 10.1016/S0306-4522(00)00400-0 · DOI
  172. Kim, 2007, Anti-glutamatergic effect of riluzole: comparison with valproic acid, Neuroscience, 147, 136, 10.1016/j.neuroscience.2007.04.018 · DOI
  173. Sha, 2017, Pharmacologic inhibition of Hsp90 to prevent GLT-1 degradation as an effective therapy for epilepsy, J. Exp. Med., 214, 547, 10.1084/jem.20160667 · DOI
  174. Sha, 2020, Hsp90 inhibitor HSP990 in very low dose upregulates EAAT2 and exerts potent antiepileptic activity, Theranostics, 10, 8415, 10.7150/thno.44721 · DOI
  175. Z. Yang, J. Wang, C. Yu, P. Xu, J. Zhang, Y. Peng, Z. Luo, H. Huang, J. Zeng, Z. Xu, Inhibition of p38 MAPK Signaling Regulates the Expression of EAAT2 in the Brains of Epileptic Rats, Frontiers in neurology 9 (2018) 925-925. 10.3389/fneur.2018.00925. · DOI
  176. A.C. Fontana, R. Guizzo, R. de Oliveira Beleboni, E.S.A.R. Meirelles, N.C. Coimbra, S.G. Amara, W.F. dos Santos, J. Coutinho-Netto, Purification of a neuroprotective component of Parawixia bistriata spider venom that enhances glutamate uptake, British journal of pharmacology 139 (2003) 1297-1309. 10.1038/sj.bjp.0705352. · DOI
  177. Fontana, 2007, Enhancing glutamate transport: mechanism of action of Parawixin1, a neuroprotective compound from Parawixia bistriata spider venom, Mol. Pharmacol., 72, 1228, 10.1124/mol.107.037127 · DOI
  178. Mortensen, 2015, Molecular determinants of transport stimulation of EAAT2 are located at interface between the trimerization and substrate transport domains, J. Neurochem., 133, 199, 10.1111/jnc.13047 · DOI
  179. Kortagere, 2018, Identification of Novel Allosteric Modulators of Glutamate Transporter EAAT2, ACS Chem. Neurosci., 9, 522, 10.1021/acschemneuro.7b00308 · DOI
  180. Falcucci, 2019, Novel Positive Allosteric Modulators of Glutamate Transport Have Neuroprotective Properties in an in Vitro Excitotoxic Model, ACS Chem. Neurosci., 10, 3437, 10.1021/acschemneuro.9b00061 · DOI
  181. Forster, 2020, Elucidation of the structure and synthesis of neuroprotective low molecular mass components of the Parawixia bistriata spider venom, ACS Chem. Neurosci., 10.1021/acschemneuro.0c00007 · DOI
  182. Fachim, 2015, Neuroprotective activity of parawixin 10, a compound isolated from Parawixia bistriata spider venom (Araneidae: Araneae) in rats undergoing intrahippocampal NMDA microinjection, Pharmacogn. Mag., 11, 579, 10.4103/0973-1296.160450 · DOI
  183. Fachim, 2011, Neurobiological activity of Parawixin 10, a novel anticonvulsant compound isolated from Parawixia bistriata spider venom (Araneidae: Araneae), Epilepsy Behav. E&B, 22, 158, 10.1016/j.yebeh.2011.05.008 · DOI
  184. Liberato, 2014, 034 & #x2014; (LIB0083) Parawixin10: A new natural compound from Parawixia bistriata spider venom that presents neuroprotective, memory-saving, and disease-modifying effects in the pilocarpine model of TLE in Wistar rats, Epilepsy Behav., 38, 196, 10.1016/j.yebeh.2014.08.067 · DOI
  185. Storck, 1992, Structure, expression, and functional analysis of a Na(+)-dependent glutamate/aspartate transporter from rat brain, PNAS, 89, 10955, 10.1073/pnas.89.22.10955 · DOI
  186. Tanaka, 1993, Expression cloning of a rat glutamate transporter, Neurosci. Res., 16, 149, 10.1016/0168-0102(93)90082-2 · DOI
  187. J.L. Arriza, W.A. Fairman, J.I. Wadiche, G.H. Murdoch, M.P. Kavanaugh, S.G. Amara, Functional comparisons of three glutamate transporter subtypes cloned from human motor cortex, The Journal of neuroscience : the official journal of the Society for Neuroscience 14 (1994) 5559-5569. · DOI
  188. Kanai, 1992, Primary structure and functional characterization of a high-affinity glutamate transporter, Nature, 360, 467, 10.1038/360467a0 · DOI
  189. Fairman, 1995, An excitatory amino-acid transporter with properties of a ligand-gated chloride channel, Nature, 375, 599, 10.1038/375599a0 · DOI
  190. Arriza, 1997, Excitatory amino acid transporter 5, a retinal glutamate transporter coupled to a chloride conductance, PNAS, 94, 4155, 10.1073/pnas.94.8.4155 · DOI
  191. É. Vigneault, O. Poirel, M. Riad, J. Prud'homme, S. Dumas, G. Turecki, C. Fasano, N. Mechawar, S. El Mestikawy, Distribution of vesicular glutamate transporters in the human brain, Front Neuroanat 9 (2015) 23-23. 10.3389/fnana.2015.00023. · DOI
  192. Bellocchio, 2000, Uptake of glutamate into synaptic vesicles by an inorganic phosphate transporter, Science, 289, 957, 10.1126/science.289.5481.957 · DOI
  193. Takamori, 2000, Identification of a vesicular glutamate transporter that defines a glutamatergic phenotype in neurons, Nature, 407, 189, 10.1038/35025070 · DOI · Paper page
  194. Fremeau, 2001, The expression of vesicular glutamate transporters defines two classes of excitatory synapse, Neuron, 31, 247, 10.1016/S0896-6273(01)00344-0 · DOI
  195. Fremeau, 2002, The identification of vesicular glutamate transporter 3 suggests novel modes of signaling by glutamate, Proc. Natl. Acad. Sci., 99, 14488, 10.1073/pnas.222546799 · DOI
  196. Cho, 1990, Uptake of Glutamate and Cystine in C-6 Glioma Cells and in Cultured Astrocytes, J. Neurochem., 55, 2091, 10.1111/j.1471-4159.1990.tb05800.x · DOI
  197. Piani, 1994, Involvement of the cystine transport system xc- in the macrophage-induced glutamate-dependent cytotoxicity to neurons, J Immunol, 152, 3578, 10.4049/jimmunol.152.7.3578 · DOI
  198. Bridges, 2012, System xc- cystine/glutamate antiporter: an update on molecular pharmacology and roles within the CNS, Br. J. Pharmacol., 165, 20, 10.1111/j.1476-5381.2011.01480.x · DOI

Cited by

Sorted by citations

Metadata

Authors
Green, J. L., dos Santos, W. F., & Fontana, A. C. K.
Venue
Biochemical Pharmacology
Publisher
Elsevier BV
Published
2021-11
Volume
193
Pages
114786
ISSN
0006-2952
DOI
10.1016/j.bcp.2021.114786
PMC
PMC8605998
Cited by
150
References
5
Language
en
Licence
Funders
  • Drexel University
  • National Institutes of Health (NS111767)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review